Increasing cancer incidences, ongoing research and development on HDAC inhibitors for the treatment of cancer and other diseases, and the potential of HDAC inhibitors to improve the effectiveness of new therapies are the major market drivers for this market. Increasing collaborations and huge investments will ensure significant growth opportunities in the near future. In fact, the parent epigenetics market is expected to grow at a CAGR of around 30% worldwide from 2013 to 2020. On the other hand, reimbursement and uncertainty issues may serve as market restraints. Research Beam Model: Research Beam Product ID: 20852 5370 USD New
Histone Deacetylase Inhibitors Market - Analysis, Growth, Global Share, Industry Overview, Trends Opportunities and Forecast 2012 - 2020
 

Histone Deacetylase Inhibitors Market - Analysis, Growth, Global Share, Industry Overview, Trends Opportunities and Forecast 2012 - 2020

Histone Deacetylase Inhibitors Market - Analysis, Growth, Global Share, Industry Overview, Trends Opportunities and Forecast 2012 - 2020

Category : Pharmaceuticals




TOLL FREE
+1-971-202-1575
------------ Or -------------
help@researchbeam.com

The Histone deactylase inhibitor (HDAC) is a molecule that consists of different compounds that form a group of anticancer agents. The parent epigenetic market of HDAC is expected to grow at a CAGR of around 30% worldwide from 2013 to 2020. The factors driving this market are increase in cancer incidences, ongoing research and development for the treatment of cancer, other diseases, and the need to improve the effectiveness of new therapies. The major limitation of this market is reimbursement and uncertainty issues. The opportunities for this market are increase in collaborations and huge investments in manufacturing which will ensure significant growth.

Key market players of this market are, Celgene, Acetylon Pharmaceuticals, Celleron Therapeutics, Envivo Pharmaceuticals, Novartis, Merck & Co., and Pfizer.

KEY BENEFITS:

• The report provides Market attractiveness analysis for the most attractive geographical region worldwide, and considers factors responsible for rapid growth in the regions. 
• Various economic factors which are significant in determining market trend, buying decisions and market attractiveness are been analyzed for market estimation and forecasting
• The report evaluates the key factors of drivers, restraints and opportunities enabling strategic decision making with perceptive to identify potential market.
• The study also discusses various environmental and regulatory factors critical for the market growth.
• The analysis will support stakeholders such as manufacturers and distributors in identifying and capturing markets with high potential.

KEY MARKET SEGMENTS

GLOBAL MARKET BY, CLASS
• Class I HDACs
• Class II HDACs
• Class III HDACs

GLOBAL MARKET BY, APPLICATIONS
• Cancer
• Central Nervous System Disorders
• Other Diseases

GLOBAL MARKET BY, GEOGRAPHY
• Europe
• North America
• Asia - Pacific
• RoW

KEY AUDIENCES:
• Health care centers
• Research facilities
• Academic institutes
• Pharmaceutical companies

 

TENTATIVE TABLE OF CONTENTS:

1. INTRODUCTION
   1.1. Objectives
   1.2. Key Benefits
   1.3. Key Deliverables
2. EXECUTIVE SUMMARY
3. MARKET OVERVIEW
   3.1. Market Definition and Scope
   3.2. Key Findings
      3.2.1. Top Factors Impacting Long term evolution market
      3.2.2. Top Investment Pockets
      3.2.3. Top winning strategies
   3.3. Porter’s Five force Analysis
   3.4. Government Regulations
   3.5. Value chain analysis
   3.6. Case Studies
   3.7. Market Dynamics
     3.7.1. Drivers
     3.7.2. Restraints
     3.7.3. Opportunities
4. GLOBAL MARKET BY CLASS, 2012-2020 $MILLIONS
    4.1. Class I HDACs
    4.2. Class II HDACs
    4.3. Class III HDACs
5. GLOBAL MARKET BY APPLICATIONS, 2012-2020 $MILLIONS
    5.1. Cancer
    5.2. Central Nervous System Disorders
    5.3. Other Diseases
6. GLOBAL MARKET BY GEOGRAPHY, 2012-2020 $MILLIONS
     6.1. Europe
     6.2. North America
     6.3.  Asia Pacific
     6.4.  RoW
7. COMPANY PROFILE
    7.1. Celgene
    7.2. Acetylon Pharmaceuticals
    7.3. Celleron Therapeutics
    7.4. Envivo Pharmaceuticals
    7.5. Novartis, Merck & Co.
    7.6. Pfizer

Enquiry Before Buy